title: Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system.
abstract: OBJECTIVE
  To evaluate the efficacy of mifepristone to reduce intermenstrual bleeding in levonorgestrel intrauterine system (LNG-IUS) users.
  
  
  METHODS
  In this prospective, open-label, comparative study, 36 women using the LNG-IUS for menorrhagia received 100mg of mifepristone every 30 days for 3 months (group 1). Fifty age-matched LNG-IUS users who did not receive any drugs were used as the comparison group (group 2). Menstrual bleeding days, pictorial blood loss assessment chart (PBAC) score, and intermenstrual bleeding/spotting days were compared between the 2 groups at 3 months (during treatment) and at 6 months (3 months post treatment).
  
  
  RESULTS
  Baseline characteristics were comparable between the groups. At 3 months, median duration and episodes of intermenstrual bleeding/spotting were significantly lower in group 1 compared with group 2 (6 vs 12.5 days, P=0.01; 2.5 vs 3, P=0.05, respectively). More women were satisfied with the LNG-IUS in the mifepristone group compared with the control group (75% vs 44%; P=0.004). At 6 months, the median duration of intermenstrual bleeding/spotting was significantly lower in group 1 compared with group 2 (6 vs 15 days; P=0.008).
  
  
  CONCLUSIONS
  Mifepristone was effective in reducing the number of episodes and duration of intermenstrual bleeding/spotting in LNG-IUS users.
authors.affiliation: Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi 110029, India.
authors.forename: Suman
authors.initials: S
authors.lastname: Lal
authors.forename: Alka
authors.initials: A
authors.lastname: Kriplani
authors.forename: Vidushi
authors.initials: V
authors.lastname: Kulshrestha
authors.forename: Meenakshi
authors.initials: M
authors.lastname: Sharma
authors.forename: Nutan
authors.initials: N
authors.lastname: Agarwal
mesh_terms: D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects*; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects*; D008796:Metrorrhagia / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D015735:Mifepristone / Q000008:administration & dosage / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011446:Prospective Studies; D014621:Vagina / Q000187:drug effects / Q000473:pathology; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D015735:Mifepristone; D016912:Levonorgestrel